Renal steatosis is a potential biomarker for obesity-related renal disease and this has been suggested as underlying biological pathway of renoprotective effects of Liraglutide in type 2 diabetes (T2DM). Proton magnetic resonance spectroscopy (¹H-MRS) has the ability to non-invasively quantify triglycerides. We examined the reproducibility of ¹H-MRS in healthy volunteers, and explored the application in a clinical trial evaluating the differences in renal triglyceride content after 9-month treatment with liraglutide. We demonstrated that ¹H-MRS is a reproducible technique and comparison with healthy volunteers suggests increased renal triglycerides in T2DM. Renoprotective effects of liraglutide might be based on reduced renal triglycerides.
This abstract and the presentation materials are available to members only; a login is required.